Trial intelligence / Profile preview

CAPTEM therapy for unresectable neuroendocrine tumor

jRCTs031180261Completed

Sponsor
Yokohama City University Hospital
Start
Oct 2016
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Open-label, single-arm trial of capecitabine and temozolomide in apudoma (NET), sponsored by Yokohama City University Hospital. Primary endpoint: Response rate. Started Oct 2016; status: completed.

02

Drugs

capecitabinetemozolomide
03

Conditions

apudoma (NET)

Beyond the preview

Go deeper on jRCTs031180261.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCTs031180261.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call